USD
+$0.00
(+0.00%
)At Close (As of Oct 13, 2025)
$679.20M
Market Cap
-
P/E Ratio
-4.37
EPS
$6.55
52 Week High
$2.11
52 Week Low
HEALTHCARE
Sector
Field | Value (EUR) |
---|---|
Gross Profit | $9.2M |
Total Revenue | $9.2M |
Cost Of Revenue | - |
Costof Goods And Services Sold | - |
Operating Income | -$98M |
Selling General And Administrative | $15M |
Research And Development | $91M |
Operating Expenses | $107M |
Investment Income Net | - |
Net Interest Income | -$11M |
Interest Income | $1.1M |
Interest Expense | $12M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $5.2M |
Income Before Tax | -$184M |
Income Tax Expense | $313K |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$184M |
Comprehensive Income Net Of Tax | - |
Ebit | -$172M |
Ebitda | -$167M |
Net Income | -$184M |
Field | Value (EUR) |
---|---|
Total Assets | $119M |
Total Current Assets | $112M |
Cash And Cash Equivalents At Carrying Value | $97M |
Cash And Short Term Investments | $97M |
Inventory | $0 |
Current Net Receivables | $12M |
Total Non Current Assets | $7.5M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $48K |
Intangible Assets Excluding Goodwill | $48K |
Goodwill | - |
Investments | - |
Long Term Investments | $1.1M |
Short Term Investments | $0 |
Other Current Assets | $2.8M |
Other Non Current Assets | - |
Total Liabilities | $226M |
Total Current Liabilities | $121M |
Current Accounts Payable | $33M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $5.9M |
Total Non Current Liabilities | $105M |
Capital Lease Obligations | $4.7M |
Long Term Debt | $46M |
Current Long Term Debt | $3.3M |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $54M |
Other Current Liabilities | $78M |
Other Non Current Liabilities | $30M |
Total Shareholder Equity | -$107M |
Treasury Stock | - |
Retained Earnings | -$184M |
Common Stock | $957K |
Common Stock Shares Outstanding | $52M |
Field | Value (EUR) |
---|---|
Operating Cashflow | -$86M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $5.2M |
Capital Expenditures | $333K |
Change In Receivables | - |
Change In Inventory | $417K |
Profit Loss | - |
Cashflow From Investment | $8.7M |
Cashflow From Financing | $146M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$184M |
Field | Value (EUR) |
---|---|
Gross Profit | $9.2M |
Total Revenue | $9.2M |
Cost Of Revenue | - |
Costof Goods And Services Sold | - |
Operating Income | -$98M |
Selling General And Administrative | $15M |
Research And Development | $91M |
Operating Expenses | $107M |
Investment Income Net | - |
Net Interest Income | -$11M |
Interest Income | $1.1M |
Interest Expense | $12M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $5.2M |
Income Before Tax | -$184M |
Income Tax Expense | $313K |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$184M |
Comprehensive Income Net Of Tax | - |
Ebit | -$172M |
Ebitda | -$167M |
Net Income | -$184M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Inventiva SA (IVA) is a clinical-stage biopharmaceutical company headquartered in Daix, France, specializing in the discovery and development of innovative oral small molecule therapies targeting diseases with high unmet medical needs, including non-alcoholic steatohepatitis (NASH) and mucopolysaccharidosis (MPS). The company's robust pipeline is driven by a commitment to address complex metabolic and rare diseases through its proprietary drug candidates, positioning it as a key player in the evolving biopharmaceutical landscape. As Inventiva advances toward pivotal clinical trials, it holds the potential to significantly impact patient outcomes and capture value within the biotechnology sector.